Please login to the form below

Not currently logged in
Email:
Password:

Endocyte

This page shows the latest Endocyte news and features for those working in and with pharma, biotech and healthcare.

Merck's vintafolide fails ovarian cancer trial

Merck's vintafolide fails ovarian cancer trial

Merck's vintafolide fails ovarian cancer trial. Major blow for drug’ s original developers Endocyte. ... Shares in Endocyte are currently hovering above $6.50, having traded as high as $33.70 in the last 12 months.

Latest news

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    it. Staying in the orphan disease area the CHMP also gave the nod to Endocyte's Vynfinit (vintafolide), a treatment for platinum-resistant ovarian cancer, along with two companion diagnostic drugs

  • Boehringer/Lilly's empagliflozin among CHMP recommendations Boehringer/Lilly's empagliflozin among CHMP recommendations

    There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Endocyte's vintafolide is a folate-targeted conjugate composed of a folate molecule plus a vinca alkaloid, which acts as a microtubule destabilising agent. ... Phase III studies of vintafolide for the treatment of platinum-resistant ovarian cancer are

  • Merck's vintafolide shows its worth in ovarian cancer Merck's vintafolide shows its worth in ovarian cancer

    unlikely to be superior to docetaxel alone, caused a massive reduction in the shares of Endocyte, the US firm which originally developed it. ... Along with Merck, Endocyte has been "building up our commercial capabilities to prepare for a potential

  • AZ licenses Merck ovarian cancer drug AZ licenses Merck ovarian cancer drug

    vintafolide for ovarian cancer, which Merck licensed from Endocyte last year in a deal valued at up to $1bn.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics